Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 15, 2004Clinical Cancer ResearchOpen Access

Matrix Metalloproteinase/Tissue Inhibitors of Matrix Metalloproteinase Phenotype Identifies Poor Prognosis Colorectal Cancers

View Full Paper
Ask AI
Bookmark
Share

Authors

SCStephanie CurranOllscoil na Gaillimhe – University of GalwaySDSinclair R. DundasUniversity of AberdeenJBJenny BuxtonWestern General Hospital

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Curran et al. (2004) studied this question.

synapsesocial.com/papers/69d8fa208c03fbaff8bf02d2https://doi.org/10.1158/1078-0432.ccr-04-0424
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: Implications for MMP inhibition therapy2001 · 61 citations
  2. 2Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9.1996 · 188 citations
  3. 3Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations2002 · 2,780 citations
  4. 4Clinicopathologic and prognostic significance of matrilysin expression at the invasive front in human colorectal cancers2001 · 114 citations
  5. 5Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer2002 · 116 citations